

[Back to Search Results](#)

A Novel Wireless Ingestible Sensor System for Measurement of Medication Adherence in HIV Treatment and Prevention

Description

- [!\[\]\(30a147af384f9f71632c2ff17bc706c8_img.jpg\) Details](#)
- [!\[\]\(9b33568d5c136f08ca688ce48be37574_img.jpg\) Sub-Projects](#)
- [!\[\]\(8c93063dab026f10e159986b27c41c64_img.jpg\) Publications](#)
- [!\[\]\(8a17676a8da87a4e59299223a765e613_img.jpg\) Patents](#)
- [!\[\]\(f7fdc7cc047b770fc5fdd2c2137c07d9_img.jpg\) Outcomes](#)
- [!\[\]\(3ca549f0313858650ddae522dc3cfea6_img.jpg\) Clinical Studies](#)
- [!\[\]\(b6026cac39735f17b6ea8953e5327900_img.jpg\) News and More](#)
- [!\[\]\(7e162357375a287a75d78d6b99984a4b_img.jpg\) History](#)
- [!\[\]\(17fbc2f440f4c1d85c1121a996c73050_img.jpg\) Similar Projects](#)

Description

Abstract Text

DESCRIPTION (provided by applicant): Advances in the last decade have transformed HIV-1 infection into a chronic disease through the use of highly active antiretroviral (ARV) therapy. Recent studies suggest the ARVs used as pre-exposure prophylaxis (PrEP) to prevent HIV infection have the potential to transform the HIV **pandemic**. However, the success of ARVs in both the treatment and prevention of HIV is critically dependent on taking medications exactly as prescribed (adherence). To date, no reliable, accurate measurement for ARV adherence exists. This proposal will evaluate the use of a novel sensor platform termed the Digital Health Feedback System (DHFS) for real- time adherence monitoring in HIV-infected persons starting ARVs and in persons at high risk for HIV infection starting PrEP. Aim 1: Develop selected digitized ARVs for use within the DHFS. We will combine an edible sensor with commonly used ARVs within a gelcap to allow the DHFS to detect when a person takes their medication. Outcomes will include successful development of a 'digitized' panel of ARVs to use with the DHFS, which are tested against USP guidelines and safe for use in clinical settings. Aim 2: Evaluate the use, acceptability, validity, and utility of the DHFS for longitudinal monitoring of adherence during initial ARV therapy. We will assess if the DHFS is acceptable to persons living with HIV that are initiating ARV treatment for the first time. Outcomes include acceptability as measured through validated questionnaires and persistence of use by participants, positive detection accuracy of the DHFS as measured by directly observed ingestions at study visits, and medication adherence as measured by DHFS. Aim 3: Evaluate the acceptability, validity, and utility of the DHFS for longitudinal monitoring of ARVs used in HIV pre-exposure prophylaxis (PrEP). We will assess if the DHFS is acceptable to persons at high risk for HIV infection that are initiating PrEP. Outcomes include acceptability as measured through validated questionnaires and persistence of use by participants, positive detection accuracy of the DHFS as measured by directly observed ingestions at study visits, and medication adherence as measured by DHFS.

Public Health Relevance Statement

PUBLIC HEALTH RELEVANCE: Adherence to antiretroviral therapy is critical to the successful management of HIV and to the efficacy of pre-exposure prophylaxis (PrEP) in the prevention of HIV infection. This project investigates a novel medication adherence monitoring tool, the Digital Health Feedback System (DHFS), in HIV-infected persons initiating antiretroviral therapy and in persons at high risk for HIV infection initiating PrEP. The overarching goals of this proposal include evaluation of the use, validity, and acceptability of the DHFS.

NIH Spending Category

Behavioral and Social Science	Bioengineering	Clinical Research	Clinical Trials and Supportive Activities
HIV/AIDS	Infectious Diseases	Pediatric	Pediatric AIDS
			Prevention
			Women's Health

Project Terms

AIDS prevention	Adherence	Anti-Retroviral Agents	Behavior	Chronic Disease	Cities
Clinical	Detection	Development	Directly Observed Therapy	Dose	Drug Exposure
Drug Kinetics	Ensure	Evaluation	FDA approved	Feasibility Studies	Feedback
Goals	Gold	Guidelines	HIV	HIV Infections	HIV-1
Highly Active Antiretroviral Therapy			Individual	Infection	Ingestion
Intervention Studies			Measurement	Measures	Medication Systems
Outcome	Participant	Patients	Pattern	Performance	Persons
Physiological	Pilot Projects	Plasma	Prevention	Proteus	Pharmaceutical Preparations
Questionnaires					

[Read More](#)

Details

Contact PI/ Project Leader

Name
[BROWNE, SARA H.](#) 

Other PIs

Name
[BENSON, CONSTANCE ANN](#) 

Program Official

Name
[STIRRATT, MICHAEL J](#)

Thank you for your feedback!

[Back to Search Results](#)

A Novel Wireless Ingestible Sensor System for Measurement of Medication Adherence in HIV Treatment and Prevention

Description

-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Project Number	Former Number	Contact PI/Project Leader	Awardee Organization
5R01MH110057-05	1R01AI122307-01	BROWNE, SARA H.Other PIs	UNIVERSITY OF CALIFORNIA, SAN DIEGO
City	INTERNAL MEDICINE/MEDICINE	CA	Congressional District
LA JOLLA	Organization Type	52	
Country	SCHOOLS OF MEDICINE		
UNITED STATES (US)			
Other Information			
FOA	Administering Institutes or Centers	Project Start Date	20-September-2015
RFA-AI-14-071	NATIONAL INSTITUTE OF MENTAL HEALTH	Project End Date	31-July-2022
Study Section	DUNS Number	Budget Start Date	01-August-2019
ZAI1-UKS-A(S1)	804355790	Budget End Date	31-July-2022
Fiscal Year	CFDA Code		
2019	242		
Award Notice Date			
07-August-2019			

Project Funding Information for 2019

Total Funding	Direct Costs	Indirect Costs
\$688,267	\$444,043	\$244,224

Year	Funding IC	FY Total Cost by IC
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$688,267

NIH Categorical Spending

[Click here for more information on NIH Categorical Spending](#)

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$34,413	Pediatric; Pediatric AIDS;
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$96,357	Women's Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$688,267	Behavioral and Social Science; Bioengineering; Clinical Research; Clinical Trials and Supportive Activities; HIV/AIDS; Infectious Diseases; Prevention;

Sub Projects

No Sub Projects information available for 5R01MH110057-05

Publications

No Publications available for 5R01MH110057-05

Patents

No Patents information available for 5R01MH110057-05

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

Thank you for your feedback!

[Back to Search Results](#)

A Novel Wireless Ingestible Sensor System for Measurement of Medication Adherence in HIV Treatment and Prevention

Description

-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Project Number

5R01MH110057-05

Former Number

1R01AI122307-01

Contact PI/Project Leader

BROWNE, SARA

[H.Other PIs](#)

Awardee Organization

UNIVERSITY OF CALIFORNIA, SAN DIEGO

No Clinical Studies information available for 5R01MH110057-05

News and More

Related News Releases

No news release information available for 5R01MH110057-05

History

No Historical information available for 5R01MH110057-05

Similar Projects

No Similar Projects information available for 5R01MH110057-05

Thank you for your feedback!